Latest Pacific Markets News

International Graphite has arranged approximately $1.5 million in non-dilutive finance with National Australia Bank to fund construction of its Collie graphite processing facility. The project remains targeted for production building completion in Q2 2027, but the funding adds future repayment obligations as the company moves closer to commissioning.

Osteopore Limited’s half-year results show an 8% revenue drop driven by currency effects, while losses widen 14% as the company invests heavily in product development and market growth.

Nexsen Limited (ASX:NXN) reported a 30% rise in net loss to $6.55 million for FY26, driven by ongoing investment in its Group B Streptococcus rapid diagnostic and Asia-Pacific growth initiatives following its October 2025 IPO.

NEXTDC has swung to a statutory profit of $82.1 million in FY26, driven by a record 202% jump in contracted utilisation and a strategic shift in lease accounting that added a $128.8 million fair value gain. The company’s $3.4 billion capital expenditure underscores its aggressive expansion, including the opening of its first international data centre in Kuala Lumpur.

BSP Financial Group has reported an 8.4% increase in net profit to K620 million for the first half of 2026, driven by a 17.7% surge in revenue and supported by a strong capital position and strategic investments.

ReNerve Ltd (ASX:RNV) reported an 80% year-on-year revenue increase in Q4 FY26, backed by expanding product lines and a $5 million funding facility. The company is advancing FDA approvals and growing its global distribution footprint, targeting a rapidly expanding $6.19 billion nerve repair biomaterials market.

OpenLearning Limited posted a record $3.27 million in SaaS annual recurring revenue and its highest quarterly cash receipts of $1.653 million, driven by new multi-year contracts in the Philippines and Malaysia and launches of AI-driven student recruitment and employability platforms.

Island Pharmaceuticals has marked a major step forward in its antiviral program with the start of GMP manufacturing for Galidesivir, expanded USAMRIID collaboration, and FDA orphan drug designation. Regulatory approvals for compassionate use in Uganda’s Ebola outbreak and a new dose optimisation study with Texas Biomed further de-risk the pathway to approval.

ReNerve Limited delivered its strongest sales quarter ever with $211,000 in revenue, boosted by new distribution deals in Asia-Pacific and a $5 million funding facility to underpin growth.

NH3 Clean Energy (ASX:NH3) has updated investors on its WAH2 Project, aiming for commercial operations by 2030 to produce low-emissions ammonia for Asia-Pacific markets. The presentation highlights strategic advantages, partnerships, and a phased development plan amid ongoing contract and financing negotiations.

Orthocell Ltd delivered a standout FY26 with 44% revenue growth to A$13.2 million, powered by accelerating US sales of its nerve repair product Remplir and a robust cash position supporting further expansion.

ReNerve has locked in a flexible A$5 million convertible note facility with RiverFort, drawing an initial A$1.6 million to back its commercial push and US sales ramp-up.